Arca Biopharma Locks in $700 Million at $72.50 per Share, Fueling Next‑Stage R&D

Arca Biopharma, which recently rebranded its operating name to Oruka Therapeutics, Inc., sealed a $700.35 million gross‑proceeds offering on April 30. The 424B5 prospectus supplement filed with the SEC shows the company sold 9,660,000 shares at $72.50 each, leaving a net‑proceeds figure of $658.33 million after underwriting discounts and commissions of $4.35 per share.

The pricing sits squarely within the range the company floated in its earlier registration statement, signaling that investor appetite remains solid despite a broader slowdown in biotech listings. While the filing does not disclose the exact preliminary range, the fact that the final price landed at $72.50 – the upper‑mid point of the guidance cited in prior roadshow materials – suggests demand was strong enough to avoid a discounting pressure that has plagued recent offerings such as MeiraGTx’s $100 million share sale.

Who’s backing the deal? Goldman Sachs and UBS acted as joint book‑runners, with Cowen, Stifel, Leerink and Guggenheim joining as co‑underwriters. The syndicate secured a 30‑day overallotment option for up to 1,449,000 additional shares, a standard “greenshoe” that could lift total gross proceeds above $800 million if exercised.

Where the money will go Arca’s filing is blunt: the net proceeds will be used for general corporate purposes, explicitly highlighting research and development activities and working‑capital needs. No further breakdown is provided, and the company does not earmark funds for debt repayment, acquisitions or other specific projects.

Risks that now sit on the balance sheet The supplement flags several offering‑related concerns that investors should watch. The overallotment option could increase dilution beyond the 9.66 million shares already sold. Existing shareholders are subject to lock‑up restrictions that may limit supply but could also create a surge of selling pressure once they expire. Finally, the filing reiterates the broader equity‑dilution risk inherent to a clinical‑stage biotech that may need to raise additional capital before any product reaches the market.

Market backdrop Arca’s pricing comes at a time when biotech offerings are receiving mixed reactions. MarketWatch reported that MeiraGTx’s $100 million share sale saw its stock slide 18% after pricing, while a recent Oruka Therapeutics upsized offering was highlighted by Markets Insider as a notable $700 million deal. Analyst sentiment on ABIO has been cautiously optimistic, noting that the cash infusion strengthens the company’s runway to advance its ORKA‑001 and ORKA‑002 monoclonal‑antibody candidates, but also warning that the company’s limited product pipeline and reliance on a half‑life‑extension platform remain material uncertainties.

The closing of this offering gives Arca Biopharma a sizable war chest to push its pipeline forward, but the same cash‑heavy balance sheet also raises the stakes for execution. As the company moves from fundraising to clinical milestones, the market will be watching whether the $658 million can translate into regulatory approvals and, ultimately, revenue.